Suven Life Sciences Ltd. News and Updates

Name: Latest research reports of Suven Life Sciences Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Suven Life Sciences Ltd.
Rating: 5
Author: Geojit BNP Paribas

Keep track of all breaking news on Suven Life Sciences Ltd. from all sources in a single place.

Load latest

Suven Life Sciences Ltd.

21 Nov 2019

113.67

-0.93%

SUVEN LIFE SCIENCES LTD

Buy: Suven Life Sciences Ltd.

Target

Geojit BNP Paribas

Q2FY20 revenue grew by ~200% YoY on account of higher sales in CRAMS (+186%) and specialty chemicals (currently 2 products) EBITDA & PAT registered a +300% growth each YoY on account of increase in high margin commercial CRAMS sales, lower employee cost & other expenses as a percentage of sales. Clinical trial data on molecule SUVN-502 which got delayed is expected to be available in 3 weeks time and will be presented in CTAD 2019 - Alzheimer Congress at San Diego, USA ....

Suven Life Sciences Ltd. is trading below all available SMAs

Suven Life Sciences Ltd.

26 Aug 2019

113.67

-0.93%

SUVEN LIFE SCIENCES LTD

Buy: Suven Life Sciences Ltd.

Recommendation Target

Geojit BNP Paribas

Q1FY20 revenue grew by a muted 4% YoY as uptick in specialty chemicals (+55%) was offset by degrowth in CRAMS (~17%YoY) and technical services (~40%YoY). EBITDA & PAT registered a 54%/47% growth YoY on account of...

Suven Life Sciences Ltd. is trading below all available SMAs

Suven Life Sciences Ltd.

29 May 2019, 12:00AM

113.67

-0.93%

SUVEN LIFE SCIENCES LTD

Hold: Suven Life Sciences Ltd.

Recommendation Target

Geojit BNP Paribas

Q4FY19 revenue grew by 18% YoY driven by higher sales in CRAMS(~25%YoY) segment and Specialty chemicals (~16%YoY). EBITDA &PAT; registered a 15%/9% growth YoY while margin declined by 200bps in Q4FY19 and by 348bps in FY19. Molecule SUVN-502 will be presented at Alzheimer's Association International Conference at Los Angeles on 17th July 2019, which can fetch more than Rs +400cr if successful. We expect EBITDA margin to remain around 33% range for FY1921E considering lower growth momentum and maintain our...

Suven Life Sciences Ltd. has lost -20.57% in the last 6 Months

Suven Life Sciences Ltd.

28 May 2019, 12:00AM

113.67

-0.93%

Suven Life Sci

Buy: Suven Life Sciences Ltd.

Dolat Capital

Nail biting wait with SUVN 502 data announcement Suven reported a strong performance during Q4FY19. Revenue grew 19% YoY, due to a 64% YoY rise in specialty chemicals. Core CRAMS grew 4% to ` 718mn, whereas commercial CRAMS fell 23% YoY to ` 420mn (` 800mn for FY19). CTS grew 26% YoY, including Taro royalty worth ` 24mn. The management expects commercial revenue to be in the range of ` 1.3mn in FY20 and flat specialty chemicals. SUVN 502 could be a positive trigger, if the data is favourable. Based on a conservative approach, we estimate a...

Suven Life Sciences Ltd. has lost -20.57% in the last 6 Months

Suven Life Sciences Ltd.

23 May 2019

113.67

-0.93%

Company news: Suven Life Sciences

Business Line

Suven Life Sciences, a specialty biopharmaceutical company developing therapeutics in central nervous system diseases, on Thursday announced that the

Suven Life Sciences Ltd. is trading below all available SMAs

Suven Life Sciences Ltd.

13 Apr 2019

113.67

-0.93%

Suven gets US court nod to buy assets of Rising Pharmaceuticals

Business Line

Suven Life Sciences on Saturday said it has received approval from a US bankruptcy court to buy assets of Rising Pharmaceuticals through its joint ve

Suven Life Sciences Ltd. is trading below all available SMAs

Suven gets US court's approval to buy assets of Rising Pharmaceuticals

Business Standard | 13 Apr 2019

Suven Life Sciences Ltd.

10 Mar 2019

113.67

-0.93%

Suven Life inks pact to buy assets of Rising Pharma units

Business Line

Suven Life Sciences Ltd has entered into an agreement to buy the assets of Aceto Corporation's Rising Pharmaceuticals through its joint venture partne

Suven Life Sciences Ltd. has lost -20.57% in the last 6 Months

Suven Life Sciences Ltd.

08 Mar 2019

113.67

-0.93%

Suven Life Sciences enters asset purchase agreement to buy Rising Pharma

Business Standard

This potential acquisition of Rising's assets would transform Shore Suven Pharma into a strong US generic pharmaceutical company

Suven Life Sciences Ltd. has lost -20.57% in the last 6 Months

Suven Life Sciences Ltd.

07 Feb 2019

113.67

-0.93%

SUVEN LIFE SCIENCES LTD

Buy: Suven Life Sciences Ltd.

Geojit BNP Paribas

High emphasis on R&D; to provide long term stability while entry to formulations will bring margin benefits in future. CRAMS to provide steady revenue growth with 116+ active projects while a promising NCE (New Chemical Entity) pipeline of 13 molecules to drive the momentum....